Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. [electronic resource]
Producer: 20080206Description: 1323-32 p. digitalISSN:- 1078-0998
- Adalimumab
- Anti-Inflammatory Agents -- pharmacology
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Humanized
- Apoptosis -- drug effects
- Blood Cells
- Cells, Cultured
- Certolizumab Pegol
- Drug Evaluation
- Etanercept
- Granulocytes -- drug effects
- Humans
- Immunoglobulin Fab Fragments -- pharmacology
- Immunoglobulin G -- pharmacology
- Inflammatory Bowel Diseases -- drug therapy
- Infliximab
- Interleukin-1beta -- biosynthesis
- Lipopolysaccharides -- pharmacology
- Lymphocytes -- cytology
- Monocytes
- Polyethylene Glycols -- pharmacology
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.